Unlocking the Therapeutic Potential of Natural Polyphenols in Esophageal Cancer [0.03%]
天然多酚在食管癌治疗中的潜力探索
Chengu Niu,Jing Zhang,Patrick I Okolo rd
Chengu Niu
Esophageal cancer (EC), one highly malignant upper gastrointestinal cancer, is the eighth most commonly occurring cancer and the sixth leading cause of cancer-related deaths worldwide. Clinically, this malignancy is considered to be one of ...
Ioannis Kournoutas,Brittany L Siontis
Ioannis Kournoutas
Liquid biopsies represent a promising and minimally invasive approach to diagnosing and monitoring cancer. In recent years, studies across a multitude of solid organ malignancies have suggested the clinical utility of biomarkers such as cir...
Tom Wei-Wu Chen
Tom Wei-Wu Chen
Recent clinical trials have investigated immune checkpoint inhibitors (ICIs) alone, in combination with tyrosine kinase inhibitors (TKIs), or with chemotherapy in angiosarcoma, yielding mixed results across subtypes. Single-agent ICI therap...
Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients [0.03%]
针对胃癌患者的HER2靶向治疗不断变化的格局
Lijuan He,Ben Liu,Zhuanfang Wang et al.
Lijuan He et al.
Gastric cancer (GC) is a deadly disease worldwide, and trastuzumab in combination with chemotherapy has been the standard first-line treatment for HER2-positive GC following the TOGA trial. Besides adjuvant therapy, HER2-directed therapy is...
Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies [0.03%]
琥珀酸脱氢酶缺乏型胃肠间质肿瘤系统治疗的近期进展
Demitrios Dedousis,Elyse Gadra,Joseph Van Galen et al.
Demitrios Dedousis et al.
Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal soft tissue sarcomas, with an incidence of about 15 cases per million person-years. Approximately 15% of GIST develop due to succinate dehydrogenase deficiency (SDH...
Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy [0.03%]
通过VEGF/VEGFR抑制剂和免疫疗法提高结直肠癌治疗效果
Jing Jiao,You Wu,Shaoxian Wu et al.
Jing Jiao et al.
Colorectal cancer, ranking as the third most prevalent malignancy globally, substantially benefits from both immunotherapy and VEGF/VEGFR inhibitors. Nevertheless, the use of monotherapy proves inadequate in effectively tackling the heterog...
Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers [0.03%]
妇科癌症幸存者激素替代治疗的进展
Megan Gorman,Karin Shih
Megan Gorman
Symptoms of menopause and the sequelae of gynecologic cancer treatment can be severe in their physical and mental impact on patient quality of life. Survivors of certain gynecologic cancers - namely, early-stage, low-grade endometrial cance...
Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma [0.03%]
基因多态性对蛋白酶体抑制剂和免疫调节药物治疗多发性骨髓瘤疗效的影响
Fatemeh Karimi,Mojtaba Aghaei,Najmaldin Saki
Fatemeh Karimi
Multiple myeloma (MM) is classified as a lymphoproliferative disorder that remains an incurable malignancy despite improved patient survival with new drug therapies. Polymorphisms are essential in determining the effectiveness and outcome o...
Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management [0.03%]
紫杉醇相关急性疼痛综合征：其特征和管理的综述
Yoshitaka Saito
Yoshitaka Saito
Taxane-associated acute pain syndrome (T-APS) is one of the most common adverse effects of taxane treatment and significantly reduces the quality of life and activities of daily living of patients. T-APS is recognized as myalgia and arthral...
Gynecologic Cancer Screening and Prevention: State of the Science and Practice [0.03%]
妇科癌症筛查与预防：现状与实践
C Tran,H Diaz-Ayllon,D Abulez et al.
C Tran et al.
Gynecological cancers, including cervical, endometrial, ovarian, and vulvovaginal cancer, have increasing incidence and mortality globally over the last three decades. In that time, there have been advances in medical therapies and paradigm...